Clinical Trial Update: Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the combination of dinaciclib and MK-2206 in patients with unresectable pancreatic cancer (pancreatic adenocarcinoma) has been comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Dinaciclib (dinaciclib)
• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 1 | Status: COMPLETED